F

    Fortress Biotech Inc (FBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.73
    -0.03 (-1.26%)

    Market Cap: $92.38M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    +2.13%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.16-6.7%
    7d ago$-0.16-6.7%
    Current$-0.15
    Revenue Consensus
    $22M
    Range$22M - $22M
    1 analysts
    Dec 31, 2026
    EPS Consensus$2.97
    Range$2.97 - $2.97
    1 analysts
    Revenue Consensus
    $23M
    Range$23M - $23M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.97---
    Sep 26EST
    		-$-0.15---
    Jun 26
    		$-0.08N/A+60.00%Beat+84.3%
    Mar 26
    		$2.82$-0.22+1381.82%Beat+687.5%
    Dec 25
    		$-0.21$0.11-290.91%Miss+29.8%
    Sep 25
    		$0.11N/A+117.74%Beat+114.5%
    Jun 25
    		$-0.51$-0.31-64.52%Miss+30.1%
    Mar 25
    		$-0.48$-0.44-9.09%Miss+53.4%
    Dec 24
    		$-0.30N/A+60.09%Beat+76.6%
    Sep 24
    		$-0.76$-0.27-181.48%Miss+19.1%
    Jun 24
    		$-0.73$-1.22+40.16%Beat+30.5%
    Mar 24
    		$-1.03$-1.73+40.46%Beat-14.4%
    Dec 23
    		$-1.28$-1.97+35.03%Beat-326.7%
    Sep 23
    		$-0.94$-1.50+37.33%Beat+21.7%
    Jun 23
    		$-1.05$-0.90-16.67%Miss+30.0%
    Mar 23
    		$-0.90$0.45-300.00%Miss+14.3%
    Dec 22
    		$-0.30$-0.22-36.36%Miss+21.1%
    Sep 22
    		$-1.20$-1.05-14.29%Miss-114.8%
    Jun 22
    		$-1.50$-1.12-33.93%Miss+41.2%
    Mar 22
    		$-1.05$0.15-800.00%Miss+22.2%
    Dec 21
    		$-0.38$0.18-311.11%Miss-660.0%
    Sep 21
    		$8.10$-2.85+384.21%Beat+368.2%
    Jun 21
    		$-2.55$-1.80-41.67%Miss+10.2%
    Mar 21
    		$-1.35$-0.70-92.86%Miss+53.6%
    Dec 20
    		$-0.05N/A+64.29%Beat+81.5%
    Sep 20
    		$-3.02$-2.10-43.81%Miss+8.5%
    Jun 20
    		$-2.84$-2.50-13.60%Miss+21.1%
    Mar 20
    		$-2.91$-3.60+19.17%Beat-1070.0%
    Dec 19
    		$-0.27$-0.31+12.90%Beat+53.4%
    Sep 19
    		$-3.30$-5.10+35.29%Beat+40.5%
    Jun 19
    		$-3.60$-6.00+40.00%Beat+52.0%
    Mar 19
    		$0.30N/A+103.45%Beat+104.1%
    Dec 18
    		$-0.58$-0.58+0.00%Beat-163.6%
    Sep 18
    		$-5.55$-8.55+35.09%Beat+44.8%
    Jun 18
    		$-7.50$-8.80+14.77%Beat-16.3%
    Mar 18
    		$-7.35$-6.00-22.50%Miss-63.3%
    Dec 17
    		$-0.22N/A+65.08%Beat+50.0%
    Sep 17
    		$-10.05$-6.37-57.77%Miss-109.4%
    Jun 17
    		$-6.45$-4.42-45.93%Miss-
    Mar 17
    		$-4.50$-5.40+16.67%Beat-
    Dec 16
    		$-0.44$-0.31-41.94%Miss-
    Sep 16
    		$-4.80$-3.00-60.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio1.04EV/EBITDA-0.29x
    Price/FCF0.69xFCF Yield144.82%
    Profitability
    Profit Margin163.30%Operating Margin-53.50%
    ROE116.00%ROIC71.26%
    Financial Health
    Debt/Equity0.24xInterest Coverage15.79x
    Current Ratio3.96xQuick Ratio3.83x
    Trading Statistics
    Beta1.21Avg Volume708.53K
    52-Week High$4.5352-Week Low$2.18

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.83
    SMA 20$2.80
    SMA 50$3.06
    SMA 200$3.01
    EMA 10$2.81
    EMA 20$2.87
    EMA 50$2.93
    EMA 200$2.86

    MACD

    Line: -0.07Signal: -0.07Hist: 0.00

    ADX

    ADX: 12.8+DI: 15.9-DI: 18.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down48.0
    PSAR$2.99

    Bollinger Bands

    Upper Band$2.99
    Lower Band$2.62
    %B Position1303%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    42.3

    Momentum Oscillators

    Stoch %K40.9
    Stoch %D45.7
    Williams %R-66.0
    ROC (10d)-3.0%
    Momentum-0.09
    CCI (20d)-67.7
    MFI (14d)44.9

    Volatility Measures

    ATR (14d)$0.17(6.2%)
    StdDev (20d)0.09
    Hist Vol54.9%(High)

    Volume Flow

    VWAP$2.74
    OBV7.5M
    AD Line-3.9M
    CMF (20d)0.061

    Volume Metrics

    Avg Vol (20d)628.2K
    Vol Ratio0.5x
    VWMA (20d)$2.81

    Pivot Points

    R3$2.87
    R2$2.84
    R1$2.81
    Pivot Point$2.77
    S1$2.74
    S2$2.71
    S3$2.67

    Advanced Oscillators

    TSI-10.91
    Ultimate Osc48.8
    KST-96.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$18.72M$16.04M$16.08M$17.63M$16.41M$13.14M$15.16M$14.63M$14.86M$13.03M$19.95M$34.75M
    Cost of Revenue$6.14M$6.22M$5.44M$5.75M$4.94M$4.79M$4.68M$4.47M$5.73M$6.00M$2.25M$6.43M
    Gross Profit$12.57M$9.82M$10.64M$11.88M$11.47M$8.35M$10.48M$10.16M$9.13M$7.03M$17.70M$28.32M
    Operating Expenses$22.58M$17.56M$15.26M$18.69M$47.95M$30.67M$34.37M$32.25M$36.96M$43.59M$37.31M$42.08M
    R&D$805,000$540,000$-371,000$208,000$8.13M$3.94M$9.93M$9.45M$12.67M$24.84M$14.07M$20.35M
    SG&A$20.81M$15.89M$14.56M$17.41M$38.76M$25.66M$26.97M$21.99M$20.82M$17.94M$19.47M$21.73M
    Operating Income$-10,006,000$-7,739,000$-4,620,000$-6,811,000$-36,473,000$-22,317,000$-23,930,000$-22,095,000$-27,788,000$-36,566,000$-19,612,000$-13,758,000
    Interest Income$1.66M$570,000$637,000$736,000$27.75M$490,000$527,000$589,000$734,000$833,000$705,000$547,000
    Interest Expense$1.48M$3.37M$2.04M$2.74M$2.52M$2.81M$2.59M$6.21M$2.12M$2.60M$2.06M$2.53M
    Income Before Tax$922,000$142.29M$-30,734,000$8.85M$-11,654,000$-24,691,000$-65,094,000$-26,625,000$-28,824,000$0$-28,604,000$-10,583,000
    Income Tax Expense$320,000$5.13M$0$26,000$0$0$0$69,000$0$0$0$141,000
    Net Income$602,000$137.16M$-5,397,000$8.83M$-11,654,000$-24,691,000$-26,314,000$-26,694,000$-28,824,000$-39,023,000$-28,984,000$-10,724,000
    EBITDA$2.02M$147.77M$-3,143,000$12.34M$-35,278,000$-20,890,000$-24,945,000$-17,293,000$-25,489,000$-35,454,000$-25,549,000$-6,748,000
    EBIT$735,000$145.09M$-4,639,000$10.86M$-36,885,000$-22,376,000$-24,004,000$-21,005,000$-27,436,000$-37,254,000$-27,249,000$-8,596,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBIO

    News

    Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

    Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a significant 96.51% of the company's shares.

    MarketBeat•8/14/26•
    Bullish

    Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

    Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss per share of ($0.08), a significant decline compared to the prior year's net income and EPS. The company highlighted revenue growth from Journey product sales and the commercial launch of Emrosi, which offset declines in other products due to competition.

    TradingView•8/13/26•
    Somewhat-Bearish

    Crystalys Raises $130M to Advance Its Once-Daily Gout Drug

    Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key advancements include Crystalys' $130 million Series B financing for dotinurad, new royalties from launched products, and positive subgroup data for AstraZeneca's anselamimab.

    Stock Titan•8/13/26•
    Neutral

    Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

    Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of Emrosi® payer access, and positive clinical subgroup analyses for anselamimab. The company's cash and cash equivalents significantly increased to $196.6 million, positioning it for continued pipeline development and strategic initiatives.

    Yahoo Finance UK•8/13/26•
    Bullish

    Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

    Fortress Biotech (FBIO) reported strong Q2 2026 results, with consolidated net revenue increasing 14% to $18.7 million, driven by Journey Medical's net product revenue of $17.8 million. The company significantly improved its financial position, ending the quarter with $196.6 million in cash and achieving positive EBITDA. Emrosi, their lead dermatology product, showed accelerating prescription growth and improved payer coverage, with expectations for continued revenue growth and profitability in 2026.

    The Globe and Mail•8/13/26•
    Bullish

    Frequently Asked Questions About FBIO

    Does FBIO pay dividends?
    Fortress Biotech Inc (FBIO) does not currently pay a regular dividend.
    What is FBIO's P/E ratio?
    Fortress Biotech Inc has a price-to-earnings (P/E) ratio of 1.04.
    What is FBIO's market cap?
    Fortress Biotech Inc (FBIO) has a market capitalization of $92.38M with a current stock price of $2.73.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In